Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 8908 results

  1. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    Awaiting development Reference number: GID-TA11743 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]

    Awaiting development Reference number: GID-TA11667 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    In development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Ruxolitinib for Prurigo Nodularis [ID6571]

    In development Reference number: GID-TA11760 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Elinzanetant for Vasomotor symptoms [ID6544]

    Awaiting development Reference number: GID-TA11784 Expected publication date:  21 July 2027

    Technology appraisal guidance
    Awaiting development

  6. Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]

    Awaiting development Reference number: GID-TA11721 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541]

    Awaiting development Reference number: GID-TA11692 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566]

    Awaiting development Reference number: GID-TA11748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573]

    Awaiting development Reference number: GID-TA11755 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564]

    Awaiting development Reference number: GID-TA11754 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546]

    Awaiting development Reference number: GID-TA11724 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development Reference number: GID-IPG10392 Expected publication date: TBC

    Interventional procedures guidance
    In development

  13. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development Reference number: GID-TA10623 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Veligrotug for treating thyroid eye disease [ID6636]

    Awaiting development Reference number: GID-TA11839 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]

    In development Reference number: GID-TA11379 Expected publication date: TBC

    Technology appraisal guidance
    In development